Search Results

You are looking at 21 - 30 of 793 items for :

  • "screening" x
Clear All
Full access

Bernardo H. L. Goulart, Mark E. Bensink, David G. Mummy and Scott D. Ramsey

disease is rarely curable. Lung cancer screening tests can potentially reduce cancer mortality through detecting tumors at earlier stages, when treatments have higher chances of cure. 2 , 3 The NCI-sponsored National Lung Screening Trial (NLST) is the

Full access

Douglas E. Wood, Ella Kazerooni, Scott L. Baum, Mark T. Dransfield, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Ann N.C. Leung, Samir S. Makani, Pierre P. Massion, Bryan F. Meyers, Gregory A. Otterson, Kimberly Peairs, Sudhakar Pipavath, Christie Pratt-Pozo, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Peter B. Sachs, Matthew B. Schabath, Lecia V. Sequist, Betty C. Tong, William D. Travis, Stephen C. Yang, Kristina M. Gregory and Miranda Hughes

, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Lung Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Lung Cancer Screening

Full access

Amit G. Singal, Jorge A. Marrero and Adam Yopp

with cirrhosis. 2 , 6 , 7 The goals of surveillance are to detect HCC at an early stage when it is amenable to curative therapy and to reduce all-cause mortality. 8 Effective implementation of the screening process requires surveillance (obtaining an

Full access

Dawn Provenzale, Kory Jasperson, Dennis J. Ahnen, Harry Aslanian, Travis Bray, Jamie A. Cannon, Donald S. David, Dayna S. Early, Deborah Erwin, James M. Ford, Francis M. Giardiello, Samir Gupta, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, M. Sambasiva Rao, Scott E. Regenbogen, Moshe Shike, Gideon Steinbach, David Weinberg, Mary A. Dwyer, Deborah A. Freedman-Cass and Susan Darlow

, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Colorectal Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Colorectal Cancer

Full access

Toru Okuyama, Yoshiyuki Kizawa, Tatsuya Morita, Hiroya Kinoshita, Megumi Uchida, Asami Shimada, Akemi Shirado Naito and Tatsuo Akechi

distress screening, 8 , 11 but recent evidence indicates that patients with cancer may not obtain a substantial benefit from screening itself. 12 – 14 Screening is considered just one step in a comprehensive screening program that consists of detailed

Full access

Dawn Provenzale, Samir Gupta, Dennis J. Ahnen, Arnold J. Markowitz, Daniel C. Chung, Robert J. Mayer, Scott E. Regenbogen, Amie M. Blanco, Travis Bray, Gregory Cooper, Dayna S. Early, James M. Ford, Francis M. Giardiello, William Grady, Michael J. Hall, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Xavier Llor, Patrick M. Lynch, June Mikkelson, Reid M. Ness, Thomas P. Slavin Jr, Shajanpeter Sugandha, Jennifer M. Weiss, Mary A. Dwyer and Ndiya Ogba

for Colorectal Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Colorectal Cancer Screening Disclosure of Relevant Financial Relationships The NCCN staff listed below

Full access

Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Don Dizon, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, Muhammad Raza, M. Alma Rodriguez, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian and Deborah A. Freedman-Cass

appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Screening for

Full access

Anne M. Covey

“When we perform screening, we're trying to find disease at a stage where treatment is potentially curative, and screening results in improved survival at 1, 3, and 5 years,” 1 stated Anne M. Covey, MD, Professor of Radiology, Memorial Sloan

Full access

Timothy J. Wilt and Philipp Dahm

Few health issues have produced more controversy than prostate-specific antigen (PSA) screening for prostate cancer. Screening and early treatment for screen-detected disease may provide large personal and public health benefits. Prostate cancer

Full access

Barry D. Bultz, Amy Waller, Jodi Cullum, Paula Jones, Johan Halland, Shannon L. Groff, Catriona Leckie, Lisa Shirt, Scott Blanchard, Harold Lau, Jacob Easaw, Konrad Fassbender and Linda E. Carlson

/print certificate. Release date: October 25, 2013; Expiration date: October 25, 2014 Learning Objectives Upon completion of this activity, participants will be able to: Discuss the benefits that implementing a routine distress screening program had on